50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Roche’s Parkinson’s drug misses main goal in mid-stage trial

Published 19/12/2024, 14:42
Roche’s Parkinson’s drug misses main goal in mid-stage trial
RHHBY
-

Investing.com -- Roche’s experimental Parkinson’s disease drug, prasinezumab, failed to meet its primary objective in a mid-stage trial.

The Swiss pharmaceutical giant announced on Thursday that the drug did not significantly delay the progression of motor symptoms in early-stage Parkinson’s patients. This is the second setback this week for potential treatments for the neurodegenerative condition.

Earlier this week, UCB, a Belgian peer, declared that a similar Parkinson’s drug candidate developed in collaboration with Novartis (SIX:NOVN) also fell short of key objectives in a clinical trial.

Despite the setback, Roche stated that prasinezumab demonstrated potential clinical efficacy. The drug also showed positive trends on several other trial goals and was well tolerated by patients. Roche plans to continue evaluating the data and will collaborate with health authorities to determine the next steps.

Levi Garraway, Roche’s Chief Medical (TASE:PMCN) Officer, expressed belief in the drug’s potential, stating, "We believe the consistent efficacy trends from the Phase IIb study of prasinezumab merit further exploration."

The latest study, which involved an expanded patient group of 586, echoed the results of a previous Roche mid-stage trial that also yielded mixed results earlier this year.

Parkinson’s disease, which currently has no cure, affects nearly 1 million people in the U.S. and more than 10 million globally. Several companies are developing treatments that target a neuronal protein called alpha-synuclein, which is found in the brain and associated with the disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.